Integra LifeSciences Holdings Co. (NASDAQ:IART) Shares Sold by Commerce Bank

Posted by Wayne Rhoads on May 26th, 2023

Commerce Bank reduced its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART – Get Rating) by 4.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,507 shares of the life sciences company’s stock after selling 464 shares during the period. Commerce Bank’s holdings in Integra LifeSciences were worth $589,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of IART. Raymond James & Associates raised its position in shares of Integra LifeSciences by 24.5% during the 1st quarter. Raymond James & Associates now owns 40,457 shares of the life sciences company’s stock worth $2,600,000 after purchasing an additional 7,971 shares during the last quarter. MetLife Investment Management LLC raised its holdings in Integra LifeSciences by 33.4% in the 1st quarter. MetLife Investment Management LLC now owns 47,096 shares of the life sciences company’s stock valued at $3,026,000 after acquiring an additional 11,796 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in Integra LifeSciences by 10.5% in the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 26,696 shares of the life sciences company’s stock valued at $1,715,000 after acquiring an additional 2,546 shares during the last quarter. Great West Life Assurance Co. Can raised its holdings in Integra LifeSciences by 8.0% in the 1st quarter. Great West Life Assurance Co. Can now owns 40,012 shares of the life sciences company’s stock valued at $2,643,000 after acquiring an additional 2,969 shares during the last quarter. Finally, Yousif Capital Management LLC raised its holdings in Integra LifeSciences by 6.5% in the 1st quarter. Yousif Capital Management LLC now owns 40,207 shares of the life sciences company’s stock valued at $2,584,000 after acquiring an additional 2,466 shares during the last quarter. 87.60% of the stock is currently owned by institutional investors and hedge funds.

Integra LifeSciences Stock Down 1.7 %

Shares of Integra LifeSciences stock opened at $38.48 on Friday. The company has a fifty day moving average price of $53.62 and a 200 day moving average price of $55.03. The company has a current ratio of 3.65, a quick ratio of 2.40 and a debt-to-equity ratio of 0.86. Integra LifeSciences Holdings Co. has a twelve month low of $38.13 and a twelve month high of $62.99. The stock has a market cap of $3.15 billion, a price-to-earnings ratio of 18.68, a price-to-earnings-growth ratio of 1.21 and a beta of 1.15.

Integra LifeSciences (NASDAQ:IART – Get Rating) last announced its quarterly earnings results on Wednesday, April 26th. The life sciences company reported $0.74 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.74. Integra LifeSciences had a net margin of 11.00% and a return on equity of 16.29%. The firm had revenue of $380.85 million during the quarter, compared to analysts’ expectations of $373.21 million. During the same period in the prior year, the company earned $0.74 EPS. The firm’s revenue was up 1.1% on a year-over-year basis. Equities research analysts forecast that Integra LifeSciences Holdings Co. will post 3.34 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Citigroup downgraded Integra LifeSciences from a “neutral” rating to a “sell” rating and cut their price target for the company from $59.00 to $39.00 in a report on Tuesday. StockNews.com assumed coverage on Integra LifeSciences in a report on Thursday, May 18th. They issued a “buy” rating for the company. TheStreet downgraded Integra LifeSciences from a “b-” rating to a “c+” rating in a report on Monday. Truist Financial dropped their price objective on Integra LifeSciences from $58.00 to $54.00 in a report on Thursday, May 18th. Finally, JMP Securities dropped their price objective on Integra LifeSciences from $75.00 to $65.00 in a report on Thursday, April 27th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $51.14.

Insider Buying and Selling

In related news, EVP Lisa Evoli sold 3,767 shares of the company’s stock in a transaction on Monday, February 27th. The shares were sold at an average price of $57.00, for a total transaction of $214,719.00. Following the completion of the sale, the executive vice president now directly owns 18,605 shares of the company’s stock, valued at approximately $1,060,485. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Integra LifeSciences news, EVP Lisa Evoli sold 3,767 shares of the company’s stock in a transaction dated Monday, February 27th. The shares were sold at an average price of $57.00, for a total value of $214,719.00. Following the completion of the transaction, the executive vice president now directly owns 18,605 shares of the company’s stock, valued at approximately $1,060,485. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Michael J. Mcbreen sold 1,843 shares of the company’s stock in a transaction dated Tuesday, March 7th. The shares were sold at an average price of $54.29, for a total transaction of $100,056.47. Following the completion of the transaction, the executive vice president now directly owns 28,796 shares of the company’s stock, valued at $1,563,334.84. The disclosure for this sale can be found here. 4.20% of the stock is owned by corporate insiders.

Integra LifeSciences Company Profile

(Get Rating)

Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. It operates under the Codman Specialty Surgical (CSS) and Tissue Technologies (TT) segments. The CSS segment includes technologies and instrumentation used for neurosurgery, neurocritical care, and otolaryngology.